General Information


We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.

Employees: 4
Founded: 2018
Contact Information
Address 50 Tice Boulevard, Suite A26, Woodcliff Lake, NJ 07677, US
Phone Number (201) 645-4765
Web Address
View Prospectus: PaxMedica
Financial Information
Market Cap $59.1mil
Revenues $0 mil (last 12 months)
Net Income $-2.1 mil (last 12 months)
IPO Profile
Symbol PXMD
Exchange NASDAQ
Shares (millions): 2.5
Price range $5.50 - $6.50
Est. $ Volume $15.0 mil
Manager / Joint Managers The Benchmark Company/ Brookline Capital Markets
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change